公开(公告)号：US20230041229A1

公开(公告)日：2023-02-09

申请号：US17788525

申请日：2020-12-23

申请人： LungLife AI, Inc.

发明人： Shahram TAHVILIAN ,  Lara BADEN ,  Daniel GRAMAJO-LEVENTON ,  Rebecca REED ,  Bhushan GARWARE ,  Chinmay SAVADIKAR ,  Anurag PALKAR ,  Paul PAGANO

IPC分类号： G06T7/00 ,  G16H15/00 ,  G01N21/64

摘要： In some embodiments, a non-transitory processor-readable medium stores code representing instructions to be executed by a processor. The code includes code to cause the processor to receive a plurality of sets of images associated with a sample treated with fluorescence in situ hybridization (FISH) probes. Each image from that set of images is associated with a different focal length using a fluorescence microscope. Each FISH probe can selectively bind to a unique location on chromosomal DNA in the sample. The code further causes the processor to identify cell nuclei in the images. The code further causes the processor to apply a convolutional neural network (CNN) to each set of images. The CNN is configured to identify a probe indication from a plurality of probe indications for that set of images. The code further causes the processor to identify the sample as containing circulating tumor cells.

公开(公告)号：US20230266325A1

公开(公告)日：2023-08-24

申请号：US18011724

申请日：2021-06-30

申请人： LungLife AI, Inc.

发明人： Paul PAGANO ,  Daniel GRAMAJO-LEVENTON ,  Rebecca REED ,  Shahram TAHVILIAN ,  Lara BADEN ,  Ashley BROWN

IPC分类号： G01N33/574 ,  C12Q1/6886

CPC分类号： G01N33/57423 ,  C12Q1/6886 ,  C12Q2600/118 ,  G01N2333/70592

摘要： The present disclosure provides a method for of determining the level of circulating tumor cells (CTCs) in a sample having blood cells from a patient comprising obtaining a test sample from a human subject; enriching circulating tumor cells (CTC); hybridizing the enriched cells in the sample with labeled nucleic acid probes that hybridize to regions of chromosomal DNA; evaluating the signal pattern for the selected cells by detecting fluorescence in situ hybridization from cells; detecting CTCs based on the pattern of hybridization to the labeled nucleic acid probes to said selected cells; and identifying the subject at risk for the development of lung cancer when the number of CTC per sample is above a predetermined cutoff value.--